» Update of EASL guidelines on management of HCC 2018

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Update of EASL guidelines on management of HCC 2018

Dr. Catherine Frenette

Dr. Catherine Frenette discusses the recently updated EASL clinical practice guidelines on the management of hepatocellular carcinoma (HCC).

Dr. Catherine Frenette

Gastroenterologist and Hepatologist

Scripps Clinic Center for Organ and Cell Transplantation

United States (US)

Dr. Catherine Frenette

Gastroenterologist and Hepatologist

Scripps Clinic Center for Organ and Cell Transplantation

United States (US)

Catherine Frenette, MD underwent medical training at Rush Medical College in Chicago, IL. She then completed internal medicine training at Scripps Mercy Hospital in San Diego, CA, and subsequently underwent training in gastroenterology with a focus on transplant hepatology at Scripps Clinic in La Jolla, CA. Dr. Frenette currently works at the Scripps Clinic Center for Organ and Cell Transplantation where she is the Medical Director of Liver Transplantation. She is also the Medical Director of the Hepatocellular Carcinoma Program. Dr. Frenette has several active research trials as well as serving in a teaching capacity for the residents and fellows at Scripps Clinic. Dr. Frenette holds special clinical interest and expertise in liver transplantation to treat cirrhosis, hepatocellular carcinoma, autoimmune hepatitis, viral hepatitis, acute liver failure and end stage liver disease. She is a world-renowned expert in the treatment of all stages of hepatocellular carcinoma, and has done multiple national and international educational sessions on this topic. She has been awarded Fellow Status of the American Society of Transplantation, and has recently also been awarded Fellow of the American Gastroenterology Association. Relevant publications Abou-Alfa G, Yen C-J, Hsu C-H, O’Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko S, Ma J, Wan P, Shao Y-Y, Lin Z-Z, Frenette CT, O’Neil B, Schwartz L, Smith-Jones P, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen Y-C, Agajanov T, Boisserie F, De Laurenzio L, Lee R, Larson S, Cheng A, Carrasquilo J. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2017 Feb; 79(2): 421-429. doi: 10.1007/s00280-017-3241-9. Nhu QM, Knowles HJ, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol 2016 Nov; 6(3): 69-75. PMID 27035078 Yan M, Ha J, Aguilar M, Liu B, Frenette CT, Bhuket T, Wong RJ. Older patients with hepatocellular carcinoma more advanced disease, lower rates of treatment, and lower survival. J Clin Gastroenterol 2016; in press. PMID 27380460 Frenette CT. Surveillance for hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2016 Jun; 12(6): 394-6. PMID 27493599 Frenette CT. Surveillance for hepatocellular carcinoma. Clin Adv Hematol Oncol 2016 Jun; 14(6): 407-9. PMID 27379808 Ahn J, Bhuket T, Mosadeghi S, Frenette CT, Liu B, Wong RJ. End stage liver disease patients with MELD > 40 have higher waitlist mortality compared to status 1A patients. Hepatol Int Sep 2016; 10(5): 838-46. doi: 10.1007/s12072-016-9735-4. Curry MP, O’Leary JG, Bzowej N, Muir AL, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchinson JG, Brown RS Jr, Charlton Ml, ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015 Dec 31; 373(27): 2618-28. PMID 26569658 Nhu QM, Knowles HJ, Pockros PJ, Frenette CT. An unexpected pulmonary complication following transcatheter arterial chemoembolization of a small hepatocellular carcinoma. J Clin Gastroenterol 2016; 50(6): 524-5. PMID 27035078 Brown RS, O’Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Friend MW, Terrault NA, HCV-TARGET Study Group. Inteferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2016 Jan; 22(1): 24-33. PMID 26519873 Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong R. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol 2016; 50 (5): 423-430. PMID 26583267 Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette CT. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015; 6(5): 469-478. PMID 26487939 Au J, Frenette CT. Management of hepatocellular carcinoma: current status and future directions. Gut Liver 2015; 9(4): 437-448. PMID 26087860 Chiao H, Frenette CT. Solid organ transplantation: little research, big need for patients with HCV. HCV Next 2014 May/June; 1(3): 15-20. Scherschel A, Minteer WB, Frenette CT. An interesting case of inclusion body myositis after 48-week interferon treatment for hepatitis C. HCV Next 2014 Mar/Apr; 1(2): 8-10. Crissien AM, Frenette CT. Current management of hepatocellular carcinoma. Gastroenterol Hepatol 2014 Mar; 10(3): 153-61. PMID 24829542. Torres HA, Kaseb A, Mahale P, Miller E, Frenette CT. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocell Carcinoma 2014; 1: 109-14. Naugler WE, Alsina AE, Frenette CT, Rossaro L, Sellers MT. Building the multidisciplinary team for management of patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2014; doi:10.1016/j.cgh.2014.03.038. PMID 24909910 Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol 2014; 41(S2): S1-S16. PMID 24576654

Dr. Catherine Frenette has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 10 min | 2018

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download the slides

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Eisai Europe Limited.

Other programmes of interest

Prof Valentina Guarneri

Interactive patient case

28 min

(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced ...

Sep 2023

Prof. Viktor Grünwald

Interactive patient case

11 min

Optimising treatment for advanced RCC

Jun 2023

Prof. David Hong

5 min

TRK fusion-positive cancer highlights from ASCO 2022

Jun 2022

Beth Wittmer

Prof. Hans Prenen

Podcast

20 min

Podcast: management of skin toxicity with multikinase inhibitors

Jun 2022

Prof. Chiara Cremolini

2 min

Update from ASCO 2022 - Rectal cancer & mCRC

Jun 2022

Prof. Sammy Saab

15 min

Response to immunotherapy in HCC: Real-world experience and treat...

Jun 2022

Prof. Jonathan Trent

2 min

Update from ASCO 2022 - Sarcoma

Jun 2022

Prof. Jonathan Trent

0 min

[DEMO] SARCOMA CONNECT update from ASCO 2022

May 2022

Screenshot of the video by Prof. Rebecca Dent

Dr. Rebecca Dent

Prof. Chiara Cremolini

Asst. Prof. Hans Lee

Prof. Jonathan Trent

0 min

Update From ASCO 2022 - Selected LBAs

May 2022

Brenda Martone

Assoc. Prof. Alicia Morgans

Podcast

30 min

Shared decision-making in nmCRPC: Treatment considerations to mai...

Jun 2022

Assoc. Prof. Tanya Dorff

Dr. Neal Shore

Podcast

30 min

Timing of ARSI and taxanes for mCRPC

Jun 2022

Assessing the management of hepatocellular cancer in Asia

Survey

2 min

Assessing the management of hepatocellular cancer in Asia

Jun 2022

Other programmes developed by Dr. Catherine Frenette

Dr. Catherine Frenette

Gastroenterologist and Hepatologist

Scripps Clinic Center for Organ and Cell Transplantation

United States (US)

Dr. Catherine Frenette

Natasha Pinheiro

Dr. Victor Hugo Fonseca de Jesus

And others...

E-learning

60 min

Accreditation: ACCME

Toxicidades cutáneas relacionadas con la terapia dirigida en onc...

Jan 2022

Prof. Sammy Saab

Dr. Amit Singal

Dr. Irene Bargellini

And others...

0 min

HCC CONNECT review paper published in Mayo Clinic Proceedings: In...

2019

Dr. Catherine Frenette

5 min

HCC CONNECT update from AASLD 2016 #1

2016

Dr. Catherine Frenette

10 min

HCC CONNECT Update from EASL 2017

2017

Dr. Catherine Frenette

5 min

HCC screening for early diagnosis: feasibility and reality?

2017

Dr. Catherine Frenette

Dr. Amit Singal

0 min

Understanding the changing treatment landscape in HCC

2018

skin toxicity related to targeted therapy

Natasha Pinheiro

Dr. Nicole R. LeBoeuf

Dr. Victor Hugo Fonseca de Jesus

And others...

E-learning

60 min

Accreditation: ACCME

Skin toxicity related to targeted therapy: interactive e-learning

Sep 2020

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.